Salesforce
CRM
Adobe
ADBE
NVIDIA
NVDA
Oracle
ORCL
Amazon
AMZN
US Stock MarketDetailed Quotes
REGN Regeneron Pharmaceuticals
- 754.260
- +4.690+0.63%
Close Dec 4 16:00 ET
- 755.000
- +0.740+0.10%
Post 18:25 ET
82.89BMarket Cap18.66P/E (TTM)
756.130High744.140Low731.77KVolume748.560Open749.570Pre Close549.96MTurnover0.69%Turnover Ratio21.69P/E (Static)109.89MShares1211.20052wk High2.83P/B79.50BFloat Cap735.95552wk Low--Dividend TTM105.41MShs Float1211.200Historical High--Div YieldTTM1.60%Amplitude4.610Historical Low751.551Avg Price1Lot Size
Regeneron Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 10.65%3.72B | 12.32%3.55B | -0.54%3.15B | 7.76%13.12B | 0.58%3.43B | 14.53%3.36B | 10.53%3.16B | 6.64%3.16B | -24.26%12.17B | -31.05%3.41B |
| Operating revenue | 11.85%3.61B | 11.45%3.44B | -0.59%3.03B | 6.55%12.58B | -1.97%3.22B | 13.06%3.22B | 10.39%3.09B | 6.10%3.05B | -25.22%11.81B | -32.45%3.29B |
| Cost of revenue | 12.53%491.1M | 18.60%480.2M | -5.18%433.8M | 16.37%1.82B | -4.37%517M | 37.32%436.4M | 36.28%404.9M | 12.99%457.5M | -35.98%1.56B | -44.98%540.6M |
| Gross profit | 10.36%3.23B | 11.39%3.07B | 0.24%2.71B | 6.49%11.3B | 1.51%2.92B | 11.76%2.93B | 7.54%2.75B | 5.64%2.7B | -22.16%10.61B | -27.60%2.87B |
| Operating expense | 16.24%1.99B | 13.63%1.97B | 14.74%1.95B | 25.80%7.07B | 12.81%1.91B | 22.99%1.72B | 38.58%1.74B | 33.62%1.7B | 21.10%5.62B | 32.43%1.7B |
| Selling and administrative expenses | 11.54%714.4M | 16.38%758.8M | 14.62%689M | 24.36%2.63B | 11.69%737.7M | 21.05%640.5M | 36.89%652M | 33.58%601.1M | 15.95%2.12B | 18.03%660.5M |
| Research and development costs | 18.25%1.27B | 10.57%1.2B | 13.37%1.25B | 23.56%4.44B | 12.86%1.18B | 18.00%1.08B | 36.64%1.09B | 30.50%1.1B | 25.61%3.59B | 41.42%1.04B |
| Other operating expenses | 1,700.00%8M | 2,533.33%14.6M | 3,160.00%15.3M | 97.66%-2.1M | 92.42%-500K | 98.91%-500K | 96.55%-600K | 97.52%-500K | -97.15%-89.9M | 58.23%-6.6M |
| Operating profit | 2.04%1.24B | 7.58%1.09B | -24.36%758.5M | -15.23%4.23B | -14.78%1B | -1.04%1.21B | -22.22%1.02B | -22.06%1B | -44.48%4.99B | -56.22%1.18B |
| Net non-operating interest income expense | 49.78%173.6M | 65.59%164.6M | 88.34%145.4M | 319.96%422.9M | 145.57%130.4M | 319.93%115.9M | 558.28%99.4M | 1,475.51%77.2M | 975.65%100.7M | 67.51%53.1M |
| Non-operating interest income | 40.16%187.4M | 51.65%179.4M | 69.64%161.5M | 209.74%495.9M | 110.92%148.7M | 211.66%133.7M | 319.50%118.3M | 414.59%95.2M | 249.56%160.1M | --70.5M |
| Non-operating interest expense | -22.47%13.8M | -21.69%14.8M | -10.56%16.1M | 22.90%73M | 5.17%18.3M | 16.34%17.8M | 44.27%18.9M | 32.35%18M | 3.66%59.4M | 23.40%17.4M |
| Other net income (expense) | 138.73%83.7M | 1,221.21%370M | 8.47%-203.2M | -93.64%-456.8M | -84.92%14.3M | -183.60%-216.1M | 90.80%-33M | 3.65%-222M | -168.88%-235.9M | 143.89%94.8M |
| Gain on sale of security | 234.10%134.5M | 1,370.23%392.5M | -19.13%-196.2M | -2,510.58%-250.7M | -65.50%45.2M | -139.44%-100.3M | 81.12%-30.9M | 22.02%-164.7M | -97.31%10.4M | --131M |
| Special income (charges) | 43.80%-56.2M | ---23.9M | 87.34%-7.1M | 27.05%-186.1M | 0.00%-30M | ---100M | --0 | -99.64%-56.1M | -431.46%-255.1M | 37.50%-30M |
| -Less:Other special charges | -43.80%56.2M | --23.9M | -87.34%7.1M | -27.05%186.1M | 0.00%30M | --100M | ---- | 99.64%56.1M | 431.46%255.1M | --30M |
| Other non- operating income (expenses) | 134.18%5.4M | 166.67%1.4M | 108.33%100K | -327.27%-20M | 85.48%-900K | -476.19%-15.8M | -210.53%-2.1M | -113.48%-1.2M | 120.00%8.8M | 98.88%-6.2M |
| Income before tax | 34.41%1.49B | 50.35%1.63B | -18.33%700.7M | -13.57%4.2B | -13.37%1.15B | -26.43%1.11B | 12.43%1.08B | -19.14%858M | -47.90%4.86B | -47.08%1.32B |
| Income tax | 47.96%152.4M | 71.00%195.8M | -152.99%-21.3M | -52.79%245.7M | -109.40%-12M | -46.93%103M | 3.06%114.5M | -54.11%40.2M | -58.38%520.4M | -53.50%127.6M |
| Net income | 33.02%1.34B | 47.90%1.43B | -11.71%722M | -8.87%3.95B | -3.13%1.16B | -23.40%1.01B | 13.65%968.4M | -15.99%817.8M | -46.28%4.34B | -46.29%1.2B |
| Net income continuous Operations | 33.02%1.34B | 47.90%1.43B | -11.71%722M | -8.87%3.95B | -3.13%1.16B | -23.40%1.01B | 13.65%968.4M | -15.99%817.8M | -46.28%4.34B | -46.29%1.2B |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 33.02%1.34B | 47.90%1.43B | -11.71%722M | -8.87%3.95B | -3.13%1.16B | -23.40%1.01B | 13.65%968.4M | -15.99%817.8M | -46.28%4.34B | -46.29%1.2B |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 33.02%1.34B | 47.90%1.43B | -11.71%722M | -8.87%3.95B | -3.13%1.16B | -23.40%1.01B | 13.65%968.4M | -15.99%817.8M | -46.28%4.34B | -46.29%1.2B |
| Basic earnings per share | 30.80%12.4 | 46.41%13.25 | -12.30%6.7 | -8.54%37.05 | -2.77%10.88 | -22.99%9.48 | 14.56%9.05 | -16.23%7.64 | -46.98%40.51 | -46.69%11.19 |
| Diluted earnings per share | 29.81%11.54 | 46.00%12.41 | -12.55%6.27 | -9.03%34.77 | -2.95%10.19 | -23.76%8.89 | 13.79%8.5 | -16.72%7.17 | -46.89%38.22 | -46.67%10.5 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
